NCT03746067 is a Phase 1 clinical trial of TS-134 in Healthy Volunteers, sponsored by Taisho Pharmaceutical R&D Inc..

Who is sponsoring NCT03746067?

NCT03746067 is sponsored by Taisho Pharmaceutical R&D Inc..

What drugs are being tested in NCT03746067?

Interventions in NCT03746067: TS-134, Placebo.

What condition does NCT03746067 study?

NCT03746067 studies Healthy Volunteers.

Is NCT03746067 still recruiting?

NCT03746067 is currently completed. Last updated 19 November 2018.

Last reviewed 2018-11-19 · How we verify

NCT03746067

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability and Pharmacokinetics of Single Doses of TS-134 in Healthy Volunteers

Completed Phase 1 Last updated 19 November 2018

What this trial tests

Phase 1 trial testing TS-134 in Healthy Volunteers in 33 participants. Completed in 13 January 2016.

Timeline

21 August 2015

Primary endpoint
13 January 2016

13 January 2016

Quick facts

Lead sponsor	Taisho Pharmaceutical R&D Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	33
Start date	21 August 2015
Primary completion	13 January 2016
Estimated completion	13 January 2016
Sites	1 location across United States

Drugs / interventions tested

TS-134 — full drug profile →
Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →

Sponsor

Taisho Pharmaceutical R&D Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1a study involving single oral dose of TS-134 in healthy male and female subjects. The safety, tolerability and pharmacokinetics of single dose of TS-134 will be evaluated.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and pharmacokinetic profiles of MGS0274 besylate (TS-134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects.
Watanabe M, Marcy B, Kinoshita K, Fukasawa M, et al · · 2020 · cited 12× · PMID 32353162 · DOI 10.1111/bcp.14331
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds.
Biso L, Carli M, Scarselli M, Longoni B. · · 2025 · cited 8× · PMID 39857669 · DOI 10.3390/biomedicines13010085

Verify or expand the search:

Other trials of TS-134

Trials testing the same drug.

NCT03141658 — Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects · Phase 1 · completed
NCT03742791 — Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Taisho Pharmaceutical R&D Inc. trials

Trials by the same sponsor.

NCT04464239 — A Single Ascending and Repeated Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TS-142 in Healt · Phase 1 · completed
NCT03919409 — First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants · Phase 1 · completed
NCT03093025 — A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder · Phase 2 · terminated
NCT03141658 — Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects · Phase 1 · completed
NCT03742791 — Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03746067 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taisho Pharmaceutical R&D Inc.
Last refreshed: 19 November 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03746067.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing